The anti‐HER2 affibody ZHER2:342 has been labelled with 124I using a similar type of prosthetic group, N‐succinimidyl‐para‐[124I]iodobenzoate ([124I]SPIB).52 In a comparative study with [124I]trastuzumab, the total uptake radioactivity of [124I]trastuzumab in tumours was found to be higher than [124I]SPIB‐ZHER2:342, however, tumour‐to‐organ ratios were lower. The gene discussed is ERBB2; the disease is neoplasm.